October 8, 2015
A generic form of paliperidone (aka Invega) extended-release tablets is now available.
Indications: Paliperidone is an atypical antipsychotic agent indicated for treatment of schizophrenia in adults and adolescents.
Dosage and administration: For adults, initial dose is 6 mg/day, and the recommended dose is 3 to 12 mg/day. For adolescents, the initial dose is 3 mg/day, and the recommended dose is 3 to 12 mg/day depending on weight.
Efficacy and safety: In the branded drug, efficacy was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults.
Side effects/risks: Commonly observed adverse reactions were:
• Adults: extrapyramidal symptoms, tachycardia, and akathisia
• Adolescents: somnolence, akathisia, tremor, dystonia, cogwheel rigidity, anxiety, weight increased, and tachycardia
• Adults with schizoaffective disorder: extrapyramidal symptoms, somnolence, dyspepsia, constipation, weight increased, and nasopharyngitis
Source: Highlights of Prescribing Information.
www.invega.com/prescribing-information. Accessed October 7, 2015.
www.allergan.com/news/news/thomson-reuters/allergan-launches-generic-version-of-invega-palip. Accessed October 7, 2015.